Effect of Admilparant (BMS-986278), an oral LPA1 antagonist, on time to disease progression in patients with pulmonary fibrosis: a post hoc analysis of a randomized trial

Background: Admilparant (BMS-986278) is an investigational lysophosphatidic acid receptor 1 antagonist to treat idiopathic and progressive pulmonary fibrosis (IPF/PPF). The effect vs placebo (pbo) on time to disease progression (TTP) was analyzed post-hoc in a phase 2 trial (NCT04308681).

Methods: Two cohorts of patients (pts), IPF or PPF, were randomized to receive 26 weeks 30mg, 60mg Admilparant or pbo BID; antifibrotic background therapy was allowed. Disease progression was a composite of relative percent predicted forced vital capacity (ppFVC) decline≥10%, acute exacerbation, all-cause hospitalization, and all-cause mortality. Subgroup analyses were based on median ppFVC at baseline (BL). A Kaplan-Meier product-limit approach assessed time to first event over 26 weeks.

Results: 255 IPF and 114 PPF pts were included. Median ppFVC at baseline was 77.25% in the IPF and 64.70% in the PPF cohort. Treatment with 60mg delayed TTP over 26 weeks compared with pbo ([Fig. 1]). A similar trend was observed in the subgroup analysis of pts with BL ppFVC below or above median.

Conclusions: Results support further evaluation of Admilparant as option for IPF and PPF pts.

Fig. 1  Time to disease progression in patients with IPF (A) and PPF (B) Hazard ratios (HRs) were estimated using a Cox proportional hazard model.

Keywords: clinical trial; lysophosphatidic acid receptor 1 antagonist; idiopathic pulmonary fibrosis; progressive pulmonary fibrosis; admilparant

Publikationsverlauf

Artikel online veröffentlicht:
18. März 2025